# US 2023/0066798 A1 · Compositions and methods for post-operative ocular care

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0066798 A1
- Document ID: US20230066798A1
- Status: Published application
- Kind: A1
- Application number: 17/983,388
- Filed: 2022-11-08
- Published: 2023-03-02
- Earliest claimed: 2020-06-10
- Assignees: Ocular Science, Inc.
- Applicants: Ocular Science, Inc.
- Inventors: Anthony Sampietro; Damien Goldberg; Amy Frost; Brian Holdorf; Francis Mah
- Web page: https://patentgrep.com/patent/US20230066798A1

## CPC

- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/196: the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 47/02: Inorganic compounds
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are certain preservative-free ophthalmic formulations for post-operative ocular care.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method for treating an ocular condition of an eye, comprising administering a pharmaceutical composition at, in, or around the eye via a delivery device and per a predetermined dosing regimen, wherein:
the pharmaceutical composition comprises:
(a) difluprednate or a pharmaceutically acceptable salt thereof, in an amount that corresponds to 0.045% to 0.055% of difluprednate,
(b) moxifloxacin or a pharmaceutically acceptable salt thereof, in an amount that corresponds to 0.45% to 0.55% of moxifloxacin, and
(c) bromfenac or a pharmaceutically acceptable salt thereof, in an amount that corresponds to 0.0675% to 0.0825% of bromfenac;
wherein these percentages are with respect to weight per volume;
the pharmaceutical composition is free of preservatives; and
the ocular condition is care after cataract surgery, care after LASIK surgery, care for a retina of the eye after cataract surgery, care for a retina of the eye after retina surgery, in preparation for an intraocular procedure, or during the intraocular procedure.

### Claim 21 (depends on 20)

The method of claim 20, wherein the delivery device is an eye dropper.

### Claim 22 (depends on 21)

The method of claim 21, wherein the eye dropper is a multidose eye dropper.

### Claim 23 (depends on 20)

The method of claim 20, wherein the predetermined dosing regimen is once per day, twice per day, three times per day, once every other day, once per week, once every other week, or once monthly.

### Claim 24 (depends on 20)

The method of claim 20, wherein the pharmaceutical composition comprises moxifloxacin hydrochloride.

### Claim 25 (depends on 20)

The method of claim 20, wherein the pharmaceutical composition comprises bromfenac sodium.

### Claim 26 (depends on 20)

The method of claim 20, wherein the pharmaceutical composition comprises:
(a) difluprednate or a pharmaceutically acceptable salt thereof, in an amount that corresponds to about 0.05% of difluprednate,
(b) moxifloxacin or a pharmaceutically acceptable salt thereof, in an amount that corresponds to about 0.5% of moxifloxacin, and
(c) bromfenac or a pharmaceutically acceptable salt thereof, in an amount that corresponds to about 0.075% of bromfenac;
wherein these percentages are with respect to weight per volume.

### Claim 27 (depends on 26)

The method of claim 26, wherein the pharmaceutical composition comprises moxifloxacin hydrochloride.

### Claim 28 (depends on 26)

The method of claim 26, wherein the pharmaceutical composition comprises bromfenac sodium.

### Claim 29 (depends on 20)

The method of claim 20, wherein the pharmaceutical composition comprises an emulsion.

### Claim 30

A method for treating an ocular condition of an eye, comprising administering a pharmaceutical composition at, in, or around the eye via a delivery device and per a predetermined dosing regimen; wherein
the pharmaceutical composition comprises the following active pharmaceutical ingredients:
(a) difluprednate or a pharmaceutically acceptable salt thereof, in an amount that corresponds to 0.045% to 0.055% of difluprednate,
(b) moxifloxacin or a pharmaceutically acceptable salt thereof, in an amount that corresponds to 0.45% to 0.55% of moxifloxacin, and
(c) bromfenac or a pharmaceutically acceptable salt thereof, in an amount that corresponds to 0.0675% to 0.0825% of bromfenac;
wherein these percentages are with respect to weight per volume;
the pharmaceutical composition is free of preservatives;
at least two of the active pharmaceutical ingredients are compounded and stored in communication with each other; and
the method is more effective as compared to a preexisting method, wherein the preexisting method administers the at least two active pharmaceutical ingredients from at least two separate and different containers.

### Claim 31 (depends on 30)

The method of claim 30, wherein the delivery device is an eye dropper.

### Claim 32 (depends on 31)

The method of claim 31, wherein the eye dropper is a multidose eye dropper.

### Claim 33 (depends on 30)

The method of claim 30, wherein the predetermined dosing regimen is once per day, twice per day, three times per day, once every other day, once per week, once every other week, or once monthly.

### Claim 34 (depends on 30)

The method of claim 30, wherein the pharmaceutical composition comprises moxifloxacin hydrochloride.

### Claim 35 (depends on 30)

The method of claim 30, wherein the pharmaceutical composition comprises bromfenac sodium.

### Claim 36 (depends on 30)

The method of claim 30, wherein the pharmaceutical composition comprises:
(a) difluprednate or a pharmaceutically acceptable salt thereof, in an amount that corresponds to about 0.05% of difluprednate,
(b) moxifloxacin or a pharmaceutically acceptable salt thereof, in an amount that corresponds to about 0.5% of moxifloxacin, and
(c) bromfenac or a pharmaceutically acceptable salt thereof, in an amount that corresponds to about 0.075% of bromfenac;
wherein these percentages are with respect to weight per volume.

### Claim 37 (depends on 36)

The method of claim 36, wherein the pharmaceutical composition comprises moxifloxacin hydrochloride.

### Claim 38 (depends on 36)

The method of claim 36, wherein the pharmaceutical composition comprises bromfenac sodium.

### Claim 39 (depends on 30)

The method of claim 30, wherein the pharmaceutical composition comprises an emulsion.
